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The formation of amyloid deposits within human tissues is a defining feature of more than 24 
fifty medical disorders, including Alzheimer's disease. Strong genetic and histological 25 
evidence links these conditions to the process of protein aggregation, yet it has remained 26 
challenging to identify a definitive connection between aggregation and pathogenicity. Using 27 
time-resolved fluorescence microscopy of individual synthetic vesicles, we show for the 28 
Aβ42 peptide implicated in Alzheimer's disease that the disruption of lipid bilayers correlates 29 
linearly with the time course of the levels of transient oligomers generated through secondary 30 
nucleation. These findings suggest a specific role of oligomers generated through the 31 
catalytic action of fibrillar species during the protein aggregation process, in driving 32 
deleterious biological function, and establish a direct causative connection between amyloid 33 
formation and its pathological effects. 34 
Main text 35 
 36 
Neurodegenerative conditions including Alzheimer's and Parkinson's diseases [1-5] have 37 
emerged as major challenges to the health and social systems of the modern world as a result 38 
of their increasing prevalence in our ageing populations. A substantial body of data indicates 39 
that protein aggregation is a key factor underlying these disorders [6-14]. Recent progress in 40 
understanding the molecular mechanisms of aggregation has revealed that these processes 41 
typically involve a primary nucleation step, followed by the growth of the initial aggregates 42 
through an elongation process (Fig. 1a) [15-18]. Once a critical quantity of fibrils is formed, 43 
however, the aggregation reaction can be accelerated dramatically by secondary processes in 44 
which fibrils formed during the aggregation reaction promote the formation of further 45 
aggregates (Fig. 1a) [17,18]. A prominent example of such secondary processes is surface-46 
catalysed secondary nucleation, which is particularly significant for the Aβ peptides 47 
associated with Alzheimer's disease, and has been linked to a variety of mechanisms of 48 
neuronal damage [4,5,17,18]. Indeed, the disruption of the lipid bilayer within cellular 49 
membranes by oligomeric protein aggregates, and the consequent loss of Ca
2+
 homeostasis, 50 
has been proposed as a general mechanism of neurotoxicity [19-21].  51 
 In the context of Alzheimer's disease, a key objective is to connect the time 52 
dependence of lipid bilayer permeability to that of the aggregation reaction and to the 53 
resulting distribution of aggregated forms of Aβ42, the 42-residue Aβ peptide that has been 54 
most strongly linked to neurological damage. Such data would serve to establish the species 55 
and processes associated with an ongoing Aβ42 aggregation reaction that are primarily 56 
responsible for causing lipid bilayer permeability. This information would be particularly 57 
useful for elucidating the mechanisms of pathological protein aggregation, which still remain 58 
poorly understood, a possible reason for the heterogeneous outcome of clinical trials aimed at 59 
targeting amyloid formation [22-24].  60 
 To address this question, we have combined recent advances in the mechanistic 61 
analysis of experimental measurements of protein aggregation kinetics in vitro [15,25] with 62 
the development of a single molecule optochemical approach able to quantify the degree of 63 
membrane permeability resulting from the aggregation reaction at any point in time [26]. 64 
Using this platform, we reveal the dominant role of transient Aβ42 oligomers generated by 65 
secondary nucleation [27] in driving membrane permeation. 66 
 67 
Results 68 
Link between aggregation of Aβ42 and lipid bilayer permeability 69 
We first monitored the extent of membrane disruption by measuring the time dependence of 70 
the permeability of the lipid bilayers of synthetic vesicles when monomeric Aβ42 was 71 
incubated at concentrations between 2 and 4 μM under solution conditions where the kinetics 72 
of amyloid fibril formation have been shown to be highly reproducible [28] (Extended Data 73 
Figure 1 and Online Methods). We also added 2.5% molar monomer equivalents of pre-74 
formed Aβ42 fibrils (seeds) to a solution of 2μM monomeric Aβ42 (Online Methods). 75 
Addition of such seed fibrils accelerates the aggregation reaction by bypassing the primary 76 
nucleation step, providing a convenient and robust way to disentangle secondary nucleation 77 
from primary nucleation [17-18]. In each case, at specific time points, aliquots were removed 78 
from the aggregating solutions, added to lipid vesicles, and the extent of Ca
2+ 
influx measured 79 
using the optochemical method [26]. We found that the ability of the aggregation reaction 80 
mixture to induce bilayer permeability increased with time, reaching a maximum value in the 81 
growth phase that is clearly observable in bulk measurements, and then decreased during the 82 
remainder of the aggregation reaction (Figs. 1b,c). 83 
 84 
 85 
Since membrane permeation is directly linked in our assay to the aggregation process, we 86 
utilised a chemical kinetics approach to describe the time evolution of Ca
2+
 influx, Φ( ), in 87 
terms of the concentrations ( ) at time  of different types of aggregate species that could 88 
give rise to membrane permeability [16] (Fig. 1a and Supplementary Note 1). In particular, 89 
due to the transient nature of Ca
2+
 influx, these aggregate species include intermediate 90 
oligomers generated either by primary nucleation (primary oligomers) or by secondary 91 
nucleation (secondary oligomers) [27]. We used the law of mass action to represent Ca
2+
 92 
influx very generally as a power-law of the concentration of oligomers, Φ( ) ∝ ( ) , where 93 ≥ 1 is the reaction order of membrane permeation with respect to the concentration of 94 
oligomers (Supplementary Note 1). 	is a measure of the cooperativity between oligomers in 95 
causing membrane permeation. We then described the time evolution of the concentrations of 96 
primary and secondary oligomers during aggregation using a master equation 97 
(Supplementary Note 1, Eq. 1). Using approaches drawing on self-consistent field theory 98 
[16,27], we derived explicit mathematical expressions for the time course of fibril formation 99 
and for the concentrations of oligomers in these two specific mechanistic scenarios 100 
(Supplementary Note 1), and then compared each of them to the experimental data describing 101 
the extent of Ca
2+
 influx over time (Fig. 1b,c). Specifically, we first fitted globally the 102 
different kinetic traces of amyloid fibril formation to our kinetic model (Supplementary Note 103 
1, Eq. 2) to determine combined rate parameters associated with primary and secondary 104 
nucleation (Supplementary Table 1). These parameters were then implemented in the 105 
theoretical oligomer concentration curves (Supplementary Note 1, Eqs. 5 and 6), leaving the 106 
combined rates of oligomer dissociation and conversion, the proportionality constant between 107 
oligomer concentrations and the extent of Ca
2+
 influx, and the reaction order  as fitting 108 
parameters (Supplementary Table 2 and Supplementary Note 1).  109 
 This global analysis reveals that the membrane permeation data are well described by 110 
a scenario in which the large majority of the species causing lipid bilayer permeability is 111 
generated by secondary nucleation (Fig. 1c) but not by primary nucleation (Fig. 1b). Note 112 
that the former scenario (Fig. 1c) explicitly considers contributions from both primary and 113 
secondary oligomers (Supplementary Note 1, Eq. 8), even though the primary oligomers are a 114 
significant proportion of the oligomer population only during the initial stages but are 115 
otherwise outnumbered by secondary oligomers for the rest of the reaction (Extended Data 116 
Figure 2). We also note that  in comparing the different mechanistic scenarios, we consider fit 117 
quality globally across a variety of conditions (concentration, seeds), since fits to individual 118 
kinetic traces are insufficient to accept or reject a particular mechanism [16]. In particular, 119 
the inability of the primary oligomer model to describe the membrane permeation data stems 120 
from the fact that the primary nucleation pathway for Aβ42 is negligible in the presence of 121 
pre-formed fibrils (Extended Data Figure 3) [17,18]. To provide further support to the 122 
hypothesis that secondary nucleation generates the majority of species responsible for 123 
membrane permeation, we performed a set of additional experiments, where the rate of 124 
secondary nucleation was modulated by removing fibrils during aggregation through 125 
centrifugation (Online Methods). Specifically, an aggregation reaction starting with 2 μM 126 
Aβ42 (lag time close to 1 hour) was stopped after 40 minutes. The aggregation mixture was 127 
then centrifuged for 15 minutes to remove fibrils and reduce secondary nucleation. We also 128 
performed a control experiment where the aggregation was stopped at 40 minutes and 129 
restarted at 60 minutes without any centrifugation. In both cases, membrane permeation was 130 
measured at 2 hours. We found that membrane permeation is significantly reduced when the 131 
mixture is centrifuged, but there is no significant change when aggregation is only interrupted 132 
(Fig. 1d). This result is in line with the prediction that this protocol would significantly 133 
diminish the observed membrane permeation from secondary oligomers, which are now 134 
present at lower concentrations, but leave unaffected the toxicity from primary oligomers. 135 
The best global fit of the permeation data to the secondary oligomer model yields an 136 
exponent ~1.0 ± 0.1 (Fig. 2a). This finding implies that the time course of Ca2+ influx 137 
correlates with the concentration of secondary oligomers, suggesting that membrane 138 
permeation is a first order reaction with respect to the population of secondary oligomers and 139 
is thus independent of interactions between oligomers (Fig. 2b and Extended Data Figure 4a). 140 
 141 
We next investigated the question of whether the secondary oligomers are able to exert their 142 
damaging effects directly on their formation or if they have first to convert into species that 143 
are distinct from those that propagate the aggregation reaction and which possess more 144 
specific deleterious activity (‘lethal oligomers’) analogous to events described for prion 145 
diseases [29]. To this end we considered a scenario in which oligomers generated initially 146 
through secondary nucleation were assumed not to be toxic but to induce bilayer permeation 147 
only after a conversion step to such lethal oligomers over timescales comparable to, or longer 148 
than, that of the overall aggregation process (Supplementary Note 1, Eq. 9). The comparison 149 
between the model predictions and the experimental time course of membrane permeation 150 
shows, however, that this model is not able to capture the kinetics of the observed behaviour 151 
(Fig. 2c,d and Extended Data Figure 4b), implying that the oligomers generated on the 152 
surfaces of fibrils drive membrane permeation  without the need for a structural 153 
reorganization that is slow relative to the overall aggregation process. As such, this finding 154 
establishes a direct connection between the process of amyloid fibril formation and the toxic 155 
effects associated with protein oligomers. 156 
 157 
Molecular chaperones modulate lipid bilayer permeation by Aβ42 aggregation  158 
We then carried out a series of additional experiments in which the rates of key microscopic 159 
steps in the Aβ42 aggregation mechanism were modulated selectively by molecular 160 
chaperones [30,31] (Fig. 3) in order to test further the conclusion that secondary oligomers 161 
are correlated with lipid bilayer permeation. We performed experiments in the presence of 162 
the chaperone DNAJB6 (0.01% molar equivalents to monomeric Aβ42), which at this 163 
concentration has been shown to inhibit mainly primary nucleation [31] (Extended Data 164 
Figure 5), and the Brichos domain (10% molar equivalents to monomeric Aβ42), that has 165 
been shown to suppress secondary nucleation [30] (Extended Data Figure 6). The 166 
experiments were performed at low concentrations of the chaperones in order still to be able 167 
to detect a measurable degree of Ca
2+
 influx, as these chaperones are able to inhibit very 168 
effectively the levels of oligomers generated  by nucleation processes. In each case, we 169 
recorded the effect of each chaperone on the total aggregate mass concentration, as well as on 170 
the extent of Ca
2+
 influx (Fig. 3). 171 
 172 
The alterations of the rate constants for primary and secondary nucleation in the presence of 173 
the chaperones were determined by fitting the aggregate mass measurements to the analytical 174 
expression for the time course of amyloid fibril formation (Supplementary Note 1, Eq. 2 and 175 
Supplementary Table 3). These rate parameters were then used to simulate the effects of the 176 
chaperones on the population of secondary oligomers over time (Supplementary Note 1, Eq. 177 
4, solid lines), without the introduction of any additional fitting parameters. In the presence of 178 
DNAJB6 (Fig. 3a), we observed a retardation of membrane permeation that is in agreement 179 
with the reduction of the rate of primary nucleation as shown by the theoretical prediction 180 
(solid line). In the presence of Brichos, the rate and total extent of Ca
2+
 influx were observed 181 
to be reduced, in agreement with the theoretical prediction for the inhibition of secondary 182 
nucleation (Fig. 3b). Moreover, turning off secondary  nucleation increases the relative 183 
importance of oligomers generated by primary nucleation shifting the predicted peak of Ca
2+
 184 
influx to earlier times, in agreement with the experiments. We also studied the effect on 185 
membrane permeation of a mutational variant of DNAJB6, M3 (Online Methods). M3 has 186 
been found to leave the overall aggregation reaction of Aβ42 unchanged (Extended Data 187 
Figure 7a) [31], and indeed, we find here that M3 has no detectable effect on the extent of 188 
Ca
2+
 influx (Extended Data Figure 7b). Overall, therefore, the results of this study 189 
demonstrate that the oligomers generated by secondary nucleation during the aggregation of 190 
Aβ42 are the major species responsible, at least in vitro, for disrupting lipid bilayers and 191 
permitting an influx of Ca
2+
 ions into vesicles. 192 
 193 
Secondary Aβ42 oligomers in different systems 194 
Finally, we sought to investigate whether or not the predictions from our model would also 195 
allow us to rationalise the role of secondary oligomers in driving toxicity in cellular and 196 
animal models (Fig. 4). To this end, we compared our lipid bilayer permeation data with the 197 
reduction of viability of cells in culture and with the reduction of gamma oscillations in 198 
mouse brain slices, each representing a different readout of the toxic effects of aggregation in 199 
vivo [30]. In particular, we measured the maximal extent of lipid bilayer permeation in the 200 
presence of increasing concentrations of Brichos to reduce the rate of secondary nucleation 201 
and hence to reduce the production of secondary Aβ42 oligomers. We then used our 202 
theoretical model (Supplementary Note 1, Eq. 11 and Extended Data Figure 8) to predict 203 
quantitatively the concentrations of secondary oligomers in the presence of different 204 
concentrations of Brichos.  205 
The resulting solid line in Fig. 4 is able to capture the experimentally measured extent of 206 
bilayer permeation in vitro. In addition, however, the reduction in the degree of membrane 207 
disruption in the presence of Brichos correlates qualitatively with our previous in vivo 208 
experimental measurements of cell death and the impairment of gamma oscillations in mouse 209 
brain slices [30] (Fig. 4). 210 
 211 
DISCUSSION  212 
Overall, our results suggest a dominant deleterious role of secondary oligomers resulting 213 
from the aggregation of Aβ42 in vitro and in vivo. While it is likely that there are additional 214 
and more specific mechanisms of toxicity in vivo, such as interactions with receptors and 215 
other cellular components [1-5,32], our study indicates that the Aβ42 oligomers are able to 216 
cause lipid membrane disruption, which is  directly linked to cellular damage [19,20]. In this 217 
context, a variety of results obtained previously can be rationalised in terms of secondary 218 
oligomers populated during the aggregation process, since their generation requires the 219 
presence of both monomeric and fibrillar forms of the protein. Thus, for  example, the 220 
presence of seed fibrils in addition to monomeric protein in animal models has been found to 221 
induce the  formation of aggregates of Aβ42 associated with neurotoxicity within the brain 222 
[33]. In addition, the concentration-dependent induction of Aβ aggregation, and its associated 223 
detrimental effects in model organisms upon administration of pathological brain extracts 224 
[34], correlate with the observations from in vitro studies. 225 
 226 
In conclusion, our study links directly the generation of secondary oligomers in the presence 227 
of monomeric and fibrillar forms of Aβ42, to the disruption of lipid membranes. These 228 
results, therefore, show directly that aggregation of the Aβ42 peptide is specifically linked to 229 
the evolution of membrane disruption that gives rise to the type of cellular damage that has 230 
been linked to Alzheimer’s disease. 231 
 232 
Methods. Details of the experimental materials and methods, mathematical modelling, and 233 
data fitting are available in the online version of the paper. 234 
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Figure captions 338 
 339 
Figure 1. Link between aggregation of Aβ42 and lipid bilayer permeability: secondary 340 
nucleation generates the oligomers that are associated with the lipid bilayer permeation 341 
induced by Aβ42 aggregation. (a) Schematic illustration of the network of molecular steps 342 
involved in Aβ42 aggregation and the oligomeric species with the potential to cause lipid 343 
bilayer permeability (see Supplementary Note 1 for details) [17,27]. (b)-(c) Kinetic analysis 344 
of the time evolution of the extent of Ca
2+
 influx during Aβ42 aggregation when monomeric 345 
Aβ42 was incubated under quiescent conditions at concentrations of 2 μM (first row), 3 μM 346 
(second row), 4 μM (third row), and 2 μM in the presence of 2.5% preformed seed fibrils 347 
(fourth row). (b) Best fit of experimental Ca
2+
-influx data to a kinetic model that assumes 348 
only oligomers generated by primary nucleation to be responsible for lipid bilayer permeation 349 
(Supplementary Note 1, Eq. 7, solid lines). Coefficient of determination for global fits 350 = 0.91. (c) Best fit of the same experimental data to a kinetic model that assumes 351 
oligomers generated through secondary nucleation to be responsible for Ca
2+
 influx 352 
(Supplementary Note 1, Eq. 8, solid lines). The various measurements of Ca
2+
 influx at 353 
different concentrations of Aβ42 and in the presence of pre-formed fibrils are consistent with 354 
a kinetic model where secondary nucleation generates the majority of oligomers that cause 355 
lipid bilayer permeability. The fitting parameters, the derivation of the equations and a 356 
detailed description of the analysis can be found in the Supplementary Note 1 and 357 
Supplementary Tables 1 and 2. (d) Fibril spin down experiment. An aggregation reaction 358 
starting with 2 μM monomeric Aβ42 was taken out at 40 min and put back at 60 min 359 
following centrifugation to remove fibrils (purple data) or without centrifugation (green 360 
data). The bar charts show the measured for the extent of Ca
2+
 influx at 2 hours. Error bars 361 
indicate the standard error of the mean (SEM) over triplicates. 362 
 363 
Figure 2. Role of oligomer cooperativity and structural reorganization. (a)-(b) Best fit of 364 
experimental Ca
2+
-influx data to a secondary oligomer kinetic model with reaction order 365 = 1 (low oligomer cooperativity, (a)) and > 1 (high oligomer cooperativity, (b); fit 366 
shown here for = 3, see Extended Data Figure 4a). (c)-(d) Analysis of membrane 367 
permeation measurements using a kinetic model that assumes that oligomers generated 368 
initially through secondary nucleation are not damaging upon their formation, but are 369 
required to convert into species that are able to induce bilayer permeation. The theoretical 370 
predictions were generated assuming either fast (1/ ≪ , (c)) or slow 1/ ≳ , (d); see 371 
Extended Data Figure 4b) rate of toxic conversion compared to the characteristic 372 
proliferation rate of the aggregation reaction ( ) [16]. This analysis shows that, in order to 373 
describe the membrane permeation data, it is not necessary to invoke a slow conversion step 374 
of oligomers into species that are able to induce bilayer permeation. If such a conversion step 375 
exists, it must occur on a timescale that is faster than that of the overall aggregation process. 376 
Error bars indicate the standard error of the mean (SEM) over triplicates. 377 
 378 
Figure 3. Molecular chaperones modulate lipid bilayer permeation induced by the 379 
aggregation of Aβ42. (a)-(b) The effects of two different types of molecular chaperone on 380 
lipid bilayer permeability were measured as monomeric Aβ42 was incubated at a 381 
concentration of 2 μM under quiescent conditions in the presence of (a) DNAJB6 (0.01% 382 
molar equivalents to monomeric Aβ42) or (b) Brichos (10% molar equivalents to monomeric 383 
Aβ42). The plots show both the time evolution of amyloid fibril formation and of Ca2+ influx 384 
in the absence and presence of the respective chaperone. We first fitted our measurements of 385 
fibril mass formation to the analytical expression for the aggregation time course 386 
(Supplementary Note 1, Eq. 2) to determine how the effective rates of primary and secondary 387 
nucleation are affected by the chaperones (solid lines). The rate parameters extracted from 388 
the analysis (Supplementary Table 3) were then implemented in the analytical expression for 389 
the concentration of secondary oligomers (Supplementary Note 1, Eq. 4) to predict the 390 
modulation of lipid bilayer permeability (solid lines). Except for the reduction of the rates of 391 
primary and secondary nucleation, the parameters used for calculating the theoretical curves 392 
for Ca
2+
 influx were the same as in Fig. 1c. The data in (a) and (b) agree with a model in 393 
which membrane permeation correlates with the levels of oligomers generated by secondary 394 
nucleation. Indeed, in such a model, inhibiting primary nucleation using DNAJB6 delays the 395 
build-up, but does not reduce significantly the total concentration of oligomers. Inhibiting 396 
secondary nucleation using Brichos, however, reduces significantly the total level of 397 
oligomers. The bar charts show the relative maximal extent of Ca
2+
 influx induced by the 398 
aggregation of 2 μM Aβ42 in the absence and presence of DNAJB6 and Brichos, 399 
respectively. Error bars indicate the standard error of the mean (SEM) over triplicates. 400 
 401 
Figure 4. Common role of secondary Aβ42 oligomers in generating aggregation-402 
associated damage in different systems. Common role of secondary Aβ42 oligomers in 403 
generating aggregation-associated damage in different systems. The presence of increasing 404 
concentrations of Brichos reduces the experimentally measured maximal levels of lipid 405 
bilayer permeability (green triangles). These measurements are consistent with the theoretical 406 
prediction of the reduction of Aβ42 oligomers generated by secondary nucleation (solid line, 407 
see Supplementary Note 1, Eq. 11). Error bars indicate the standard error of the mean (SEM) 408 
over triplicates. Moreover, the reduction in lipid bilayer permeability in the presence of 50% 409 
molar equivalents of Brichos correlates broadly with the observed reduction of the viability 410 
of cells in culture (blue circles) and the reduced loss in gamma oscillation in mouse brain 411 
slices (pink squares). The cell and mouse brain slice data are taken from Ref. [30]. 412 
 413 
Online Methods 414 
 415 
Preparation and purification of recombinant Aβ42 416 
The recombinant Aβ42 (M1-42) peptide (MDAEFRHDSGYEVHHQKLVFF 417 
AEDVGSNKGAIIGLMVGGVVIA), here called Aβ42, was expressed in the Escherichia coli 418 
BL21 Gold (DE3) strain and purified as described previously with slight modifications 419 
[25,35]. 420 
 421 
Preparation of recombinant Aβ42 for kinetic experiments 422 
Solutions of monomeric recombinant Aβ42 were prepared as previously described by 423 
dissolving the lyophilised Aβ42 peptide in 6 M GuHCl then purifying the protein using a 424 
Superdex 75 10/300 GL column (GE Healthcare Bio-Sciences AB SE-751 84 Uppsala, 425 
Sweden). The centre of the elution peak was collected, and the peptide concentration was 426 
determined from the absorbance of the integrated peak area using ε280 = 1490 L mol-1cm-1. 427 
 428 
Measurement of aggregation kinetics of Aβ42 429 
For kinetic experiments the Aβ42 monomer was diluted with buffer and supplemented with 430 
20 μM ThT. All samples were prepared in low-binding Eppendorf tubes (Eppendorf AG, 431 
Hamburg, Germany) on ice. Each sample was then pipetted into multiple wells of a 96-well 432 
half-area, low-binding polyethylene glycol coating plate (Corning 3881, Kennebuck ME, 433 
USA) with a clear bottom, at 80 μL per well. The 96-well plate was placed in a plate reader 434 
(Fluostar Omega, Fluostar Optima, or Fluostar Galaxy; BMG Labtech, Ortenberg, Germany) 435 
and incubated at 37
ο
C under quiescent conditions using the bottom reading mode (440-nm 436 
excitation filter, 480-nm emission filter). For each new preparation of protein, the 437 
aggregation kinetics were checked by performing reactions at different concentrations of 438 
Aβ42. 439 
 440 
Aβ42 aggregation 441 
Aβ42 aggregation reactions were performed in 20 mM sodium phosphate buffer, pH 8, 442 
supplemented with 20 μM ThT and 200 μM EDTA. Samples were prepared in low-binding 443 
Eppendorf tubes on ice by avoiding any introduction of air bubbles. All aggregation reactions 444 
were performed in a 96-well half area, low-binding, clear-bottom PEG coated plate (Corning 445 
3881, Kennebuck ME, USA). Plates were sealed to prevent any evaporation. Aggregation 446 
assays were performed at 37
ο
C under quiescent conditions. Aliquots for measurements of 447 
Ca
2+
 influx were then taken into low-binding tubes at the desired times after the plate was 448 
placed in the incubator. 449 
 450 
Seeded aggregation 451 
Pre-formed fibrils of Aβ42, which are used as seed, were prepared just before the experiment. 452 
Fibrils were prepared by aggregating 4 μM Aβ42 for overnight in 20 mM sodium phosphate, 453 
200 μM EDTA, pH 8.0 and 20 μM ThT. ThT fluorescence was monitored over time to ensure 454 
that the fibrils were formed. Then samples were collected from the wells into low-binding 455 
Eppendorf tubes and sonicated for 2 min in a sonicator bath at room temperature. Under this 456 
condition, the final concentration of fibrils (4 μM Aβ42) was considered to be equal to the 457 
initial concentration of the monomer, as there was negligible presence of free monomer left 458 
in solution. Preformed Aβ42 fibrils (2.5%) were subsequently added to the 2 μM freshly 459 
prepared monomer solution to perform seeded aggregation. This aggregation reaction was 460 
also performed in 20 mM sodium phosphate, 20 μM ThT, 200 μM EDTA at pH 8.0at 37οC 461 
under quiescent conditions. 462 
 463 
Preparation and purification of the BRICHOS domain 464 
proSP-C Brichos was expressed in E. coli and purified as described previously [36]. 465 
 466 
Preparation and purification of the chaperone DNAJB6 and its mutational variant M3 467 
Human DNAJB6b (isoform b, UniProt ID O75190-2) with a hexa-His tag was expressed 468 
recombinantly in E. coli ER2566 and purified as described previously [31] but with an 469 
additional washing step using 8 M urea during the affinity chromatography in order to 470 
remove bound bacterial proteins [37]. Just prior to its use, DNAJB6 was dialysed into the 471 
assay buffer (20 mm sodium phosphate buffer pH 8, 0.2 mm EDTA, 0.02% sodium azide) 472 
using Slide-A-Lyser MINI (Thermo Scientific, Rockford, IL). 473 
 474 
Preparation and purification of dye filled vesicles 475 
The dye filled vesicles were prepared as previously described [26]. Phospholipids 16:0-18:1 476 
PC (catalogue no - 850457) and biotinylated lipids 18:1-12:0 Biotin PC (catalogue no - 477 
860563) were purchased from Avanti Polar Lipids (Alabama, USA) in the form of powder 478 
and chloroform solutions respectively. Chloroform stock solutions were mixed such that the 479 
ratio between 16:0-18:1 PC and 18:1-12:0 biotin PC was 100:1, and the chloroform was then 480 
removed under vacuum in a desiccator overnight. The samples were then dissolved in 481 
HEPES buffer (pH 6.5) with 100 μM Cal-520 and five freeze-and-thaw cycles were 482 
performed using dry ice and a water bath. The solution was passed at least 10 times through 483 
an extruder (Avanti Polar Lipids, Alabama, USA) with a membrane of an appropriate size cut 484 
off of 200 μm. The size of the vesicles was determined using a Zetasizer (Zetasizer Nano 485 
ZSP, Malvern Instruments, Malvern, UK). To separate non-incorporated dye molecules from 486 
the solution surrounding the vesicles, size-exclusion chromatography was performed [26]. 487 
 488 
Preparation of PEGylated slides and immobilization of single vesicles 489 
We followed the previously described protocol for slide preparation to perform the 490 
membrane permeabilisation assay [26]. Borosilicate glass coverslides (VWR International, 491 
22x22 mm, product number 63 1-0122) were cleaned by subsequent sonication in 2% (v/v) 492 
Hellmanex III (Hellma GmbH & Co. KG, Muellheim, Germany) in milliQ water, twice in 493 
milliQ water, methanol and again in water for 10 min each. The glass slides were dried under 494 
a nitrogen stream, and plasma-etched using an argon plasma cleaner (PDC-002, Harrick 495 
Plasma, Ithaca, NY) for 20 minutes before Frame-Seal incubation chambers (9x9mm
2
, 496 
Biorad, Hercules, CA, product number SLF-0601) were affixed to the glass slides. 50 μL of a 497 
mixture of 100:1 PLL-g-PEG (SuSoS AG, Duebendorf, Switzerland) and PLL-g-PEG biotin 498 
(SuSoS AG, Duebendorf, Switzerland) (1 g/L) in reaction buffer (50 mM Hepes, pH 6.5) was 499 
added to the coverslide inside of the chamber and incubated for 30 min. Then the coverslides 500 
were washed 3 times with filtered reaction buffer. 50 μL of a solution of 0.1 mg/mL 501 
Neutravidin (ThermoScientific, Rockford, IL 61105, USA) in reaction buffer was added to 502 
the coverslide and incubated for 15 min, and washed 3 times with reaction buffer. Then, 50 503 
μL of the solution of purified vesicles was added to the coverslide and incubated for 30 min 504 
before washing carefully at least 5 times with reaction buffer. 505 
 506 
Imaging using Total Internal Reflection Fluorescence Microscope 507 
Imaging was performed using a homebuilt Total Internal Reflection Fluorescence 508 
Microscope (TIRFM) based on an inverted Olympus IX-71 microscope as previously 509 
described in detail [26]. A 488 nm laser (Toptica, iBeam smart, 200 mW, Munich, Germany) 510 
was used to excite the sample. The expanded and collimated laser beam was focused using 511 
two Plano-convex lens onto the back-focal plane of the 60X, 1.49NA oil immersion objective 512 
lens (APON60XO TIRF, Olympus, product number N2709400) to a spot of adjustable 513 
diameter. The fluorescence signal was collected by the same objective and was separated 514 
from the excitation beam by a dichroic (Di01-R405/488/561/635, Semrock). The emitted 515 
light was passed through an appropriate set of filters (BLP01-488R, Semrock and FF01-516 
520/44-25, Semrock). The fluorescence signal was then passed through a 2.5x beam expander 517 
and imaged onto a 512 x 512 pixel EMCCD camera (Photometrics Evolve, E VO-512-M-518 
FW-16-AC-110). Images were acquired with a 488nm laser (10 W/cm
2
) for 50 frames with a 519 
scan speed of 20 Hz and bit depth of 16 bits. Each pixel corresponds to 100 nm. All the 520 
measurements were carried out under ambient conditions (T=295K). The open source 521 
microscopy manager software Micro Manager 1.4 was used to control the microscope 522 




 influx assay using TIRFM 525 
The imaging of the induced membrane permeability was performed as previously described 526 
[26]. Single vesicles tethered to PLL-PEG coated borosilicate glass coverslides (VWR 527 
International, 22x22 mm, product number 63 1-0122) were placed on an oil immersion 528 
objective mounted on an inverted Olympus IX-71 microscope. Each coverslide was affixed to 529 
Frame-Seal incubation chambers and was incubated with 50 μL of HEPES buffer of pH 6.5. 530 
Just before the imaging, the HEPES buffer was replaced with 50 μL Ca2+ containing buffer 531 
solution L-15. 16 (4x4) images of the coverslide were recorded under three different 532 
conditions (background, in the presence of Aβ42 and after addition of ionomycin (Cambridge 533 
Bioscience Ltd, Cambridge, UK), respectively). The distance between each field of view was 534 
set to 100 μm, and was automated (bean-shell script, Micromanager) to avoid any user bias. 535 
After each measurement the script allowed the stage (Prior H117, Rockland, MA, USA) to 536 
move the field of view back to the start position such that identical fields of view could be 537 
acquired for the three different conditions.  538 
 539 
Data analysis to quantify the extent of Ca
2+
 influx 540 
The fluorescence intensity of individual vesicles was determined as previously described 541 
[26]. The recorded images were analysed using ImageJ to determine the fluorescence 542 
intensity of each spot under the three different conditions, namely background (Fbackground), in 543 
the presence of an aggregation mixture (Faggregate), and after the addition of ionomycin 544 
(Fionomycin). The relative influx of Ca
2+
 into an individual vesicle due to aggregates of Aβ42 545 
peptide was then determined using the following equation: 546 Ca 	influx = Φ = −−  
The average degree of Ca
2+
 influx was calculated by averaging the Ca
2+
 influx into individual 547 
vesicles. 548 
 549 
Fibril spin down experiment 550 
To check if the oligomers formed during secondary nucleation are the major source of 551 
species causing membrane permeabilisation, we performed an aggregation where the rate of 552 
secondary nucleation was substantially reduced by removing insoluble fibrils from the 553 
aggregation reaction. We aggregated 2 μM Aβ42 in 20 mM sodium phosphate buffer at pH 8, 554 
mixed with 20 μM ThT, 200 μM EDTA for 40 minutes in clear bottom 96 well plates (lag 555 
phase ~ 1 hour) and then arrested the aggregation by putting it to the ice bath. Immediately 556 
we then transferred the aggregation mixture into a low-binding Eppendorf and centrifuged for 557 
15 minutes at 4
ο
C to remove as many  fibrils as possible. Then we transferred the supernatant 558 
back into clear bottom 96 well plates for  60 minutes at 37
ο
C and followed the aggregation. 559 
We also performed a control experiment where the aggregation was stopped at 40 minutes 560 
using ice bath and the aggregation restarted at 60 minutes at 37
ο
C without any centrifugation. 561 
 562 
Further information on experimental design is available in the Nature Research Reporting 563 
Summary linked to this article. 564 
 565 
Code availability All simulation and data analysis codes are included in this article and its 566 
Supplementary Information. Codes are available from the corresponding authors on request.  567 
 568 
 569 
Data availability The authors confirm that all data generated and analysed during this study 570 
are included in this published article and its Supplementary Information. Source data for 571 
Figures 1,3 and 4 are available with the paper online. 572 
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